Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| TLX | PRESS-RELEASE | bullish | 8/10 | Telix Pharmaceuticals announced FDA approval of Pixclara® (floretyrosine F 18), the first FDA-approved FET-PET imaging d | Sep 14, 2026 |
| BNTX | PRESS-RELEASE | bullish | 7/10 | BioNTech and OncoC4 announced positive median overall survival (OS) data from stage 1 of the PRESERVE-003 Phase 3 trial | Sep 14, 2026 |
| MRK | COURT-RULING | neutral | 1/10 | This is a routine procedural order granting pro hac vice admission for an attorney in the ongoing case Kaiser Foundation | Sep 12, 2026 |
| UTHR | CLUSTER | neutral | 3/10 | CEO Martine Rothblatt sold ~$6.9M in open-market shares on Sep 9-10, 2026, while simultaneously exercising stock options | Sep 12, 2026 |
| CSTL | 144 | neutral | 4/10 | CEO Derek Maetzold filed a Form 144 to sell 29,014 shares of Castle Biosciences common stock, valued at approximately $9 | Sep 11, 2026 |
| ARTV | CLUSTER | neutral | 3/10 | A cluster of insider selling at Artiva Biotherapeutics, totaling $477K, was driven by the CEO, COO, CTO, and CMO. The CE | Sep 11, 2026 |
| CYTK | CLUSTER | neutral | 2/10 | Two insiders at Cytokinetics sold a combined $339K in open-market sales over a week. The EVP of R&D exercised and immedi | Sep 11, 2026 |
| ELOX | S-1 | neutral | 4/10 | Eloxx Pharmaceuticals filed an S-1 registration statement for the resale of 600,000 shares of common stock and up to 4,3 | Sep 11, 2026 |
| ACAD | 8-K | neutral | 3/10 | Acadia Pharmaceuticals settled a stockholder derivative lawsuit related to alleged misleading statements about its pimav | Sep 11, 2026 |
| ARTV | 8-K | neutral | 3/10 | Artiva Biotherapeutics held its 2026 Annual Meeting on September 8, 2026, where stockholders approved an amendment to th | Sep 11, 2026 |
| AGMB | 6-K | neutral | 2/10 | Agomab announced the appointments of Marino Garcia and Dr. Naimish Patel to its Board of Directors, approved at a Specia | Sep 11, 2026 |
| RNAZ | 8-K | bearish | 5/10 | TransCode Therapeutics CFO Thomas Fitzgerald resigned effective September 9, 2026, and was replaced by interim CFO John | Sep 11, 2026 |
| CLLS | PRESS-RELEASE | neutral | 2/10 | Cellectis announced a conference call and webcast for September 14, 2026, to provide a business update. The press releas | Sep 11, 2026 |
| CYCN | 8-K | mixed | 7/10 | Korsana Biosciences (formerly Cyclerion Therapeutics) completed its reverse merger with Korsana on September 8, 2026, ce | Sep 11, 2026 |
| BDRX | 6-K | bearish | 7/10 | No summary provided | Sep 11, 2026 |
| ZBIO | S-3ASR | neutral | 5/10 | Zenas BioPharma filed an automatic shelf registration statement (S-3ASR) to register 7,000,000 shares of common stock fo | Sep 11, 2026 |
| SUPN | DEFM14A | mixed | 7/10 | Supernus Pharmaceuticals is merging with Indivior in an all-stock merger of equals. Each Supernus share will convert int | Sep 11, 2026 |
| YARW | 424B5 | bearish | 7/10 | Yarrow Bioscience is pricing a $150M follow-on offering of 5,769,231 shares at $26.00/share, a ~10.7% discount to the pr | Sep 11, 2026 |
| AMLX | 144 | neutral | 2/10 | Two AMLX officers (James M. Frates and Camille L. Bedrosian) filed Form 144 notices on September 11, 2026, each indicati | Sep 11, 2026 |
| CRBP | PRESS-RELEASE | neutral | 5/10 | Corbus Pharmaceuticals announced a conference call for September 14 to discuss topline Phase 1b data for CRB-913, its no | Sep 11, 2026 |
| PHAR | 6-K | bullish | 7/10 | Pharming announced FDA approval of its sNDA for Joenja (leniolisib) to treat children aged 4-11 years with APDS, expandi | Sep 11, 2026 |
| INBX | 144 | neutral | 2/10 | Director Kimberly Manhard filed a Form 144 notice of intent to sell 500 shares of Inhibrx Biosciences common stock, with | Sep 11, 2026 |
| ISCO | 144 | neutral | 2/10 | Director Paul V. Maier filed a Form 144 notice of intent to sell 32,802 shares of International Stem Cell Corp (ISCO) on | Sep 11, 2026 |
| PHVS | CLUSTER | neutral | 3/10 | Two Pharvaris insiders, including President Lu Peng, sold a combined $911K in open-market sales this week. The sales fol | Sep 11, 2026 |
| ATAI | 25-NSE | bearish | 9/10 | Nasdaq filed a Form 25-NSE to remove AtaiBeckley Inc. (ATAI) common stock from listing and registration under Section 12 | Sep 11, 2026 |
| GSK | 6-K | neutral | 1/10 | This 6-K filing reports routine acquisitions of GSK ordinary shares by multiple PDMRs (senior executives) under the comp | Sep 11, 2026 |
| LLY | PRESS-RELEASE | bullish | 5/10 | Eli Lilly completed its acquisition of AtaiBeckley, a clinical-stage biopharma developing neuroplastogens for mental hea | Sep 11, 2026 |
| CRNX | 15-12G | bullish | 9/10 | Crinetics Pharmaceuticals filed Form 15-12G to terminate its SEC registration under Section 12(g), effective September 1 | Sep 11, 2026 |
| BIAF | 8-K | neutral | 3/10 | bioAffinity Technologies filed an 8-K furnishing investor presentation materials for the H.C. Wainwright 28th Annual Glo | Sep 11, 2026 |
| IFF | ANALYST-UPGRADE | neutral | 2/10 | Keybanc initiated coverage on International Flavors & Fragrances Inc (IFF) at Sector Weight with no price target, a neut | Sep 11, 2026 |